• Haralampos T H Dinopoulos and Peter V Giannoudis.
• University of Leeds, Academic Department of Trauma & Orthopaedics, School of Medicine, St. James's University Hospital, Beckett Street, Leeds, West Yorkshire, LS9 7TF, UK.
• Expert Opin Drug Saf. 2006 Nov 1; 5 (6): 847-66.

AbstractDemineralised bone matrix (DBM) acts as an osteoconductive, and possibly as an osteoinductive, material. It is widely used in orthopaedic, neurosurgical, plastic and dental areas. More than 500,000 bone grafting procedures with DBM are performed annually in the US. It does not offer structural support, but it is well suited for filling bone defects and cavities. The osteoinductive nature of DBM is presumably attributed to the presence of matrix-associated bone morphogenetic proteins (BMPs) and growth factors, which are made available to the host environment by the demineralisation process. Clinical results have not been uniformly favourable; however, a variable clinical response is attributed partly to nonuniform processing methods found among numerous bone banks and commercial suppliers. DBMs remain reasonably safe and effective products. The ultimate safe bone-graft substitute, one that is osteoconductive, osteoinductive, osteogenic and mechanically strong, remains elusive.

16 keywords...

hide…